News & Publications

November 15, 2021

Treventis attends RESI Nov 2021

Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year...
Read More
September 17, 2021

Treventis CSO Mark Reed gives invited lecture at Undruggable Leaders Forum

From September 15-16, 2021, the “Undruggable Leaders Forum” was a virtual meeting focused on new approaches to historically intractable targets....
Read More
September 15, 2021

Treventis attends RESI Partnering Week 2021

For the first time in several years, Treventis CEO Christopher Barden attended the Redefining Early Stage Investments (RESI) conference (held...
Read More
July 31, 2021

Treventis attends Virtual AAIC 2021

Treventis was well represented at the Alzheimer Association International Conference, running from Jul 26-30, 2021 (held virtually and in Denver,...
Read More
June 16, 2021

Treventis attends BIO Digital Conference

Treventis was represented at the BIO Digital International Convention (for a second year in a row, held virtually due to...
Read More
March 17, 2021

Treventis presents at the Targeting Protein Misfolding Summit

Treventis VP Research Dr. Marcia Taylor was an invited speaker at the Targeting Protein Misfolding Summit, held virtually from March...
Read More
March 15, 2021

Treventis VP Research Marcia Taylor attends AD/PD 2021

Dr. Marcia Taylor was in attendance at the virtual AD/PD conference taking that took place on March 9-14, 2021. This...
Read More
December 9, 2020

Treventis scientists and advisors attend and present at ALS/MND 2020

Treventis scientists Drs. Christopher Barden and Ross Mancini and SAB member Dr. Janice Robertson attended the 31st Virtual International Symposium...
Read More
August 1, 2020

Treventis attends Virtual AAIC 2020

Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the...
Read More
July 8, 2020

Treventis founders awarded funding for COVID-19 clinical trial

LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to...
Read More